ArticleClinical breast cancer2025
Hidden Costs of Endocrine Therapy for Black Breast Cancer Survivors: A Qualitative Examination of Patient and Provider Experiences.
Article in Clinical breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundNon-adherence to endocrine therapy (ET) remains an unsolved clinical issue that decreases rates of survival. Non-white race and socioeconomic status have been associated with ET non-adherence, but the reasons for these disparities are unclear. Addressing this issue effectively requires the characterization of the contributing factors to these inequities. This qualitative study aims to explore the influence of race and socioeconomic status on ET adherence through the perspectives of Black breast cancer survivors (BCS) and oncology providers.
methodsWe conducted individual semi-structured interviews with 24 Black BCS and 9 providers at a single cancer center.
resultsBCS had a median age of 55 years (IQR = 17 years). About 1/4 had ≤high school diploma (26.1%) and 37.7% completed ≥college education. About 1/3 of BCS had annual household incomes of ≤$40,000 (30.4%), $40,000 to $100,000 (34.8%), or ≥$100,000 (34.8%). Forty-three percent of BCS had private insurance; 39.1% were insured through Medicaid, Medicare, or the federal healthcare exchange; 13% were uninsured. Five qualitative themes emerged from both patients and providers: (1) Limited access to initial and continued care; (2) patient discomfort, distrust, and fear of discrimination; (3) cost of ET can be a barrier to adherence; (4) costs of managing symptoms can be a barrier to adherence; and (5) time toxicity - time and effort needed to coordinate symptom management.
conclusionsIn addition to cost of ET medications, we identified additional financial and time toxicity related to side-effect management. Black BCS face a myriad of costs which can potentially impact ET adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.